ReviewProceedings of the American Thoracic Society2007
Strategies for identifying modifier genes in cystic fibrosis.
Review in Proceedings of the American Thoracic Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comprehensive Overview of Common Polymorphic Variants in Genes Related to Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2021Pooled it
- Role of theInternational journal of molecular sciences · 2025Article
- Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine.Journal of clinical medicine · 2021Review
- Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis.Disease models & mechanisms · 2016Article
- Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.Glycoconjugate journal · 2015Review
- Different course of lung disease in two siblings with novel ABCA3 mutations.European journal of pediatrics · 2014Article
- Quantitative proteomic profiling reveals differentially regulated proteins in cystic fibrosis cells.Journal of proteome research · 2014Article
- Biokinetics of nanoparticles and susceptibility to particulate exposure in a murine model of cystic fibrosis.Particle and fibre toxicology · 2014Article
- Article
- Genetic influences on cystic fibrosis lung disease severity.Frontiers in pharmacology · 2013Article
- The ABCC6 transporter: what lessons can be learnt from other ATP-binding cassette transporters?Frontiers in genetics · 2013Article
- Saturation of the human phenome.Current genomics · 2010Article
- Myeloperoxidase-dependent oxidative metabolism of nitric oxide in the cystic fibrosis airway.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2010Article
- Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients.Journal of applied genetics · 2010Article
- Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.Respiratory research · 2009Article
- Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.Human mutation · 2009Article
- Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity.PloS one · 2009Article
- Atypical cystic fibrosis and CFTR-related diseases.Clinical reviews in allergy & immunology · 2008Review
- Congenital tracheal malformation in cystic fibrosis transmembrane conductance regulator-deficient mice.The Journal of physiology · 2008Article
- Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature.Current psychiatry reports · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Even in patients with cystic fibrosis (CF) with identical CFTR genotypes, there is a wide range in the severity of lung disease, with some individuals facing death or lung transplantation early in life and others demonstrating mild lung disease well into adulthood. Although numerous environmental factors have been identified that influence CF pulmonary phenotype, there is now growing evidence that polymorphic variants in genes besides CFTR play an important role in determining severity of CF lung disease. This article reviews the most recent findings regarding genetic modifiers in CF and also discusses in detail the strategies currently being used to identify novel modifiers of CF pulmonary phenotype. These include single- and multicenter studies, twin and sib studies, microarray approaches, and whole genome association studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.